Listed

XBiotech Inc.: Form 10-Q for the period ended Mar 31, 2021

Filed with the SEC on May 10, 2021 and accepted by EDGAR at May 10, 2021, 17:15 ET.

Share

Management's discussion and analysis

As filed, 18,452 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Overview

XBiotech Inc. (“XBiotech” or the “Company) is a pre-market biopharmaceutical company engaged in discovering and developing True Human™ monoclonal antibodies for treating a variety of diseases. True Human™ monoclonal antibodies are those which occur naturally in human beings—as opposed to being derived from animal immunization or otherwise engineered. We believe that naturally occurring monoclonal antibodies have the potential to be safer and more effective than their non-naturally occurring counterparts. XBiotech is focused on developing its True Human™ pipeline and manufacturing system.

After the Janssen Transaction in December 2019 and the tender offer in February 2020, we had retained earnings of $95.0 million. We had net losses of $2.6 million and $0.3 million for the three months ended March 31, 2021 and 2020, respectively. During the next year, we expect that the revenues from Janssen Transaction will generate enough cash for our research and development activities. However, the term of the clinical manufacturing agreement will end on December 31, 2021. In addition, we expect to incur significant and increasing operating losses for the foreseeable future as we advance our drug candidates from discovery through preclinical testing and clinical trials and seek regulatory approval and eventual commercialization. In addition to these increasing research and development expenses, we expect general and administrative costs to increase as we continue to operate as a public company. We will need to generate significant revenues to achieve or sustain profitability, and we may never do so. As of March 31, 2021, we had 95 employees.

Revenues

Prior to receiving payments under the clinical manufacturing agreement entered into in connection with the Janssen Transaction, we had not generated any revenue. Under the clinical manufacturing agreement, we manufacture bermekimab for use by Janssen in clinical trials, in exchange for fixed payments, paid in quarterly installments through 2021. Following the end of 2021, the agreement will expire and we will not be entitled to receive any more such revenues. In addition, we entered into a transition services agreement under which we agreed to continue operational management, on a fee-for-service basis, of certain ongoing clinical trials related to bermekimab. Our ability to generate any additional revenue and/or to become profitable (or sustain any profitability) depends on our ability to successfully commercialize any product candidates we may advance in the future.

Research and Development Expenses

Research and development expense consists of expenses incurred in connection with identifying and developing our drug candidates. These expenses consist primarily of salaries and related expenses, stock-based compensation, the purchase of equipment, laboratory and manufacturing supplies, facility costs, costs for preclinical and clinical research, development of quality control systems, quality assurance programs and manufacturing processes. We charge all research and development expenses to operating expenses as incurred.

Clinical development timelines, likelihood of success and total costs vary widely. We do not currently track our internal research and development costs or our personnel and related costs on an individual drug candidate basis. We use our research and development resources, including employees and our drug discovery technology, across multiple drug development programs. As a result, we cannot state precisely the costs incurred for each of our research and development programs or our clinical and preclinical drug candidates. From inception through March 31, 2021, we have recorded total research and development expenses, including share-based compensation, of $223.9 million. Our total research and development expenses for the three months ended March 31, 2021 and 2020 were $4.6 million and $1.2 million, respectively. Share-based compensation accounted for $363 thousand and $533 thousand for the three months ended March 31, 2021 and 2020, respectively.

Research and development expenses, as a percentage of total operating expenses for the three months ended March 31, 2021 and 2020 were 76% and 22%, respectively. The percentages, excluding stock-based compensation, for the three months ended March 31, 2021 and 2020, were 82% and 25%, respectively.

The clinical development costs may further increase going forward with potentially more advanced studies in the future as we evaluate our clinical data and pipeline.

Based on the results of our preclinical studies, we anticipate that we will select drug candidates and research projects for further development on an ongoing basis in response to their preclinical and clinical success and commercial potential. For research and development candidates in early stages of development, it is premature to estimate when material net cash inflows from these projects might occur.

General and Administrative Expenses

General and administrative expense consists primarily of salaries and related expenses for personnel in administrative, finance, business development and human resource functions, as well as the legal costs of pursuing patent protection of our intellectual property and patent filing and maintenance expenses, stock–based compensation, and professional fees for legal services. Our total general and administration expenses for the three months ended March 31, 2021 and 2020 were $1.5 million and $4.0 million, respectively. Share-based compensation accounted for $0.5 million and $2.1 million for the three months ended March 31, 2021 and 2020, respectively.

General and administrative expense, as a percentage of total operating expenses for the three months ended March 31, 2021 and 2020 were 24% and 78%, respectively. The percentages, excluding stock-based compensation, for the three months ended March 31, 2021 and 2020, were 18% and 75%, respectively.

Critical Accounting Policies

Our Management’s Discussion and Analysis of Financial Condition and Results of Operations is based on our financial statements, which have been prepared in conformity with generally accepted accounting principles in the United States (US GAAP). The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and expenses incurred during the reported periods.

We base estimates on our historical experience, known trends and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Our significant accounting policies are more fully described in the notes to our financial statements appearing in this Quarterly Report on Form 10-Q.

Income Taxes

We account for income taxes under the asset and liability method. We record deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, as well as for operating loss and tax credit carryforwards. We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which we expect to recover or settle those temporary differences. We recognize the effect of a change in tax rates on deferred tax assets and liabilities in the results of operations in the period that includes the enactment date. We assess the likelihood that deferred tax assets will be realized, and we recognize a valuation allowance if it is more likely than not that some portion of the deferred tax assets will not be realized. This assessment requires judgment as to the likelihood and amounts of future taxable income by tax jurisdiction. To date, with the exception of certain Canada deferred tax assets that will reverse in a period in which they may be carried back, we have provided a valuation allowance against our deferred tax assets as we believe the objective and verifiable evidence of our historical pretax net losses outweighs any positive evidence of our forecasted future results. Although we believe that our tax estimates are reasonable, the ultimate tax determination involves significant judgment. We will continue to monitor the positive and negative evidence and will adjust the valuation allowance as sufficient objective positive evidence becomes available.

We account for uncertain tax positions by recognizing the financial statement effects of a tax position only when, based upon technical merits, it is more likely than not that the position will be sustained upon examination. We recognize potential accrued interest and penalties associated with unrecognized tax positions within our global operations in income tax expense.

Results of Operations

Revenue

Revenue during the three months ended March 31, 2021 and 2020 are summarized as follows (in thousands):

Revenue Three Months Ended March 31, 2021 2020
Manufacturing revenue $4,500 $3,000
Clinical Trial revenue 350 9,681
Total revenue $4,850 $12,681

Under the clinical manufacturing agreement with Janssen, we have recorded $4.5 and 3.0 million as manufacturing revenue for the three months ended March 31, 2021 and 2020, respectively. Clinical trial revenue is based on the transition services agreement under which we agreed to continue operational management, on a fee-for-service basis, of certain ongoing clinical trials related to bermekimab, which includes $269 thousand pass-through revenue for the two trials and $81 thousand mark-up revenue for the three months ended March 31,2021 and $7.4 million pass through revenue and $2.2 million mark-up revenue for the three months ended March 31, 2020.

Cost of Goods Sold

Cost of goods sold during the three months ended March 31, 2021 and 2020 are summarized as follows (in thousands):

Cost of goods sold Three Months Ended March 31, 2021 2020
Manufacturing cost $2,035 $2,166
Clinical trial cost 269 7,507
Total cost of goods sold $2,304 $9,673

18

The manufacturing cost for the three months end March 31, 2021 and 2020 represents period expense for manufacturing, quality assurance and quality control departments. Clinical trial cost for the three months end March 31, 2021 and 2020 is the pass-through expenses for two trials and other related clinical trial department expenses.

Expenses

Research and Development

Research and Development costs are summarized as follows (in thousands):

Three Months Ended March 31, 2021 2020 Increase (Decrease) % Increase (Decrease)
Salaries and related expenses $1,556 $321 $1,235 385%
Laboratory and manufacturing supplies 882 124 758 611%
Clinical trials and sponsored research 325 - 325 -
Stock-based compensation 363 533 (170) -32%
Other 1,508 177 1,331 752%
Total $4,634 $1,155 $3,479 301%

We do not currently track our internal research and development costs or our personnel and related costs on an individual drug candidate basis. We use our research and development resources, including employees and our drug discovery technology, across multiple drug development programs. As a result, we cannot state precisely the costs incurred for each of our research and development programs or our clinical and preclinical drug candidates.

Research and development expenses increased $3.5 million to $4.6 million for the three months ended March 31, 2021, compared to $1.2 million for the three months ended March 31, 2020. The increase was mainly due to the reclassification of expense. A portion of manufacturing department expenses were reclassed to cost of goods sold in 2021 compared to all manufacturing department expensed being reclassed to cost of goods sold in 2020, as all such expense incurred in 2020 were related to the clinical trial manufacturing agreement in the Janssen Transaction. Also, clinical trial expense in the three months ended March 31, 2021 is generated from the preparation for the new trials. We did not incur clinical trial expenses for the three months ended March 31, 2020, as all such expenses incurred were pursuant to the transition services agreement entered into as part of the Janssen Transaction.

General and Administrative

General and administrative costs are summarized as follows (in thousands):

Three Months Ended March 31, 2021 2020 Increase (Decrease) % Increase (Decrease)
Salaries and related expenses $256 $258 $(2) -1%
Patent filing expense 136 139 (3) -2%
Stock-based compensation 512 2,144 (1,632) -76%
Professional fees 463 938 (475) -51%
Other 98 544 (446) -82%
Total $1,465 $4,023 $(2,558) -64%

General and administrative expense decreased $2.6 million to $1.50 million for the three months ended March 31, 2021, compared to $4.0 million for the three months ended March 31, 2020. The decrease was primarily related to stock–based compensation expenses to the Chief Executive Officer in the fourth quarter of 2019 which were fully vested in the year 2020. In addition, professional fees decreased $0.5 million mainly due to professional and legal fees in the three months ended March 31, 2020 related to the tender offer completed in February 2020. Also, there was a $0.4 million decrease in other expense, because of the amortization of D&O insurance.

Other income (loss)

The following table summarizes other income (loss) (in thousands):

Three Months Ended March 31, 2021 2020
Interest income $109 $1,898
Other income (10) -
Foreign exchange gain (loss) 409 (93)
Total $508 $1,805

The interest income for the three months ended March 31, 2021 and 2020 was mainly from the interest generated from the Company’s Canadian bank account. Foreign exchange gain and loss was mainly due to the fluctuation between the US dollar and the Euro in the three months ended March 31, 2021 compared to the three months ended March 31, 2020.

Liquidity and Capital Resources

Our cash requirements could change materially as a result of the progress of our research and development and clinical programs, licensing activities, acquisitions, divestitures or other corporate developments.

Since our inception on March 22, 2005 through March 31, 2021, we have funded our operations principally through private placements and public offerings of equity securities, which have provided aggregate cash proceeds of approximately $308.4 million. We received $675 million in cash proceeds from the Janssen Transaction in the year ended December 31, 2019, and $4.9 million revenue from the manufacturing agreement and clinical trial agreement for the three months period ended as of March 31, 2021. We are expected to receive $75 million cash as the escrow receivable from the same transaction in second quarter of 2021. During this year, we expect that the revenues from Janssen Transaction will generate enough cash for our research and development activities. At March 31, 2021, we had cash and cash equivalents of $239.9 million as compared to cash and cash equivalents of $241.5 million at March 31, 2020. The following table summarizes our sources and uses of cash (in thousands):

Net cash (used in) provided by: Three Months Ended March 31, 2021 2020
Operating activities $1,809 $(60,673)
Investing activities (637) (389)
Financing activities 1,022 (412,082)
Effect of foreign exchange rate on cash and cash equivalents 319 90
Net change in cash and cash equivalents $2,513 $(473,054)

During the three months ended March 31, 2021 and 2020, our operating activities generated net cash $1.8 million and used net cash $60.7 million, respectively. The change in cash from operations for the three months ended March 31, 2021 as compared to the three months ended March 31, 2020 was mainly due to the $51.1 million income tax payment in 2020.

During the three months ended March 31, 2021 and 2020, our investing activities used net cash of $637 thousand and $389 thousand, respectively. The increase was due to costs incurred on the construction of the building extension and warehouse.

During the three months ended March 31, 2021, our financing activities provided net cash of $1.0 million, compared to used net cash of $412.1 million in the three months ended March 31, 2020. During the three months ended March 31, 2021, employees exercised stock options to purchase a total of 0.7 million shares of our common stock for approximately $1.0 million in net proceeds. During the three months ended March 31, 2020, we used approximately $420 million to repurchase 14,000,000 common shares at a price of $30.00 per share, relating to the tender offer completed in February 2020. During the three months ended March 31, 2020, employees exercised stock options to purchase a total of 1.3 million shares of our common stock for approximately $7.9 million in net proceeds.

We expect to continue to incur operating losses in the future. Although we are currently receiving clinical manufacturing revenue and clinical trial service revenue from Janssen, we will not receive any product revenue until a drug candidate has been approved by the FDA, EMA or similar regulatory agencies in other countries and successfully commercialized. Further, the clinical manufacturing agreement will expire on December 31, 2021, after which we do not expect to receive any additional revenue under that agreement. As of March 31, 2021, our principal sources of liquidity were our cash and cash equivalents, which totaled approximately $239.9 million.

Off-Balance Sheet Arrangements

Since inception, we have not engaged in any off-balance sheet activities, including the use of structured finance, special purpose entities or variable interest entities.

Market risk

As filed, 308 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The Company is not currently exposed to material market risk arising from financial instruments, changes in interest rates or commodity prices, or fluctuations in foreign currencies. The Company has no need to hedge against any of the foregoing risks and therefore currently engages in no hedging activities.

Controls and procedures

As filed, 1,783 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Management's Evaluation of our Disclosure Controls and Procedures

As of the end of the period covered by this Quarterly Report on Form 10-Q, an evaluation was carried out by the Company’s management, with the participation of the Chief Executive Officer and Principal Financial Officer, of the effectiveness of the Company’s disclosure controls and procedures, as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934. Based on such evaluation, the Chief Executive Officer and Principal Financial Officer concluded that the Company’s disclosure controls and procedures are effective to ensure that information required to be disclosed in the reports the Company files or furnishes under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and regulations, and are operating in an effective manner.

Changes in Internal Control Over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the quarter ended March 31, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Limitations on Effectiveness of Controls and Procedures

In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2021-01-01 to 2021-03-31$4.8mus-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
Cost of revenue3 months2021-01-01 to 2021-03-31$2.3mus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2021-01-01 to 2021-03-31$2.5mus-gaap:GrossProfit
Research and development3 months2021-01-01 to 2021-03-31$4.6mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2021-01-01 to 2021-03-31−$3.6mus-gaap:OperatingIncomeLoss
Income tax3 months2021-01-01 to 2021-03-31−$477.0kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2021-01-01 to 2021-03-31−$2.6mus-gaap:NetIncomeLoss
Diluted EPS3 months2021-01-01 to 2021-03-31−$0.09us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow3 months2021-01-01 to 2021-03-31$1.8mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2021-01-01 to 2021-03-31$637.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2021-03-31$239.9mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2021-03-31$327.9mus-gaap:AssetsCurrent
Total assetsAt period end2021-03-31$355.9mus-gaap:Assets
Current liabilitiesAt period end2021-03-31$2.7mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2021-03-31$3.8mus-gaap:Liabilities
Shareholders' equityAt period end2021-03-31$352.1mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001171843-21-003353. Last ingested by Listed: Nov 14, 2026, 18:14 ET. Listed shows no prices and gives no investment advice.